Protocol Ledger

NCT05904119 · Phase III · RECRUITING

Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study

Interventional Phase III clinical trial protocol NCT05904119 sponsored by European Organisation for Research and Treatment of Cancer - EORTC in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-03-15 Enrollment: 411 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05904119
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)411 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05904119
Protocol FieldVerified Registry Value
NCT IdentifierNCT05904119
Consolidated Lead SponsorEuropean Organisation for Research and Treatment of Cancer - EORTC
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment411 participants (ESTIMATED)
Registered Start Date2024-03-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05904119
Hospital Research SiteLocationSite Profile
Cliniques Universitaires Saint-LucBrussels, BelgiumOpen Hospital Dossier ->
Universitair Ziekenhuis GentGhent, BelgiumOpen Hospital Dossier ->
Universitaetsklinikum EssenEssen, GermanyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI